Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

PALI
Palisade Bio, Inc. Common Stock
stock NASDAQ

Market Open
Nov 7, 2025 12:26:08 PM EST
1.54USD-6.364%(-0.11)2,041,235
1.54Bid   1.55Ask   0.01Spread
Pre-market
Nov 7, 2025 9:28:30 AM EST
1.63USD-1.212%(-0.02)12,787
After-hours
Nov 6, 2025 4:39:30 PM EST
1.65USD-0.302%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 29, 2021
08:30AM EST  Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual   GlobeNewswire Inc
Dec 8, 2021
08:21AM EST  Palisade Bio Reports Granted New US Patent Covering Protease Inhibitor LB1148 For Treating Adhesions, Postoperative Ileus   Benzinga
08:00AM EST  Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bios Patent Portfolio   GlobeNewswire Inc
Nov 30, 2021
08:00AM EST  Palisade Bio, Inc.(NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications,today announced that the company will be granted a patent from the European Patent Office (EPO) covering its lead investigational drug product, LB1148.The patent will publish on December 22, 2021, and provide protection until 2035.   GlobeNewswire Inc
Nov 23, 2021
08:00AM EST  Palisade Bio, Inc.(NASDAQ: PALI), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications (the Company), today announced that it had made equity grants to three new employees under its 2021 Inducement Plan (the Plan).   GlobeNewswire Inc
Nov 22, 2021
01:57PM EST  Palisade Bio Granted European Patent Titled 'COMPOSITIONS FOR THE TREATMENT OF AUTODIGESTION'   Benzinga
Nov 15, 2021
10:57AM EST  Palisade Bio Q3 EPS $0.42   Benzinga
07:00AM EST  Palisade Bio, Inc.(Nasdaq: PALI) (Palisade or the Company), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the third quarter ended September 30, 2021.   GlobeNewswire Inc
Oct 22, 2021
08:03AM EDT  Palisade Bio Reports Sale Of Seneca Asset NSI-189 For Treatment Of Central Nervous System Disorders For Upfront Cash Payment Of ~$400K, Up To Added $4.5M In Potential Milestone Payments   Benzinga
08:00AM EDT  Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the   GlobeNewswire Inc
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 9, 2021
08:30AM EDT  Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph.D. will present at the H.C. Wainwright Global Investment Conference, which is being held virtually from September 13- 15, 2021.   GlobeNewswire Inc
Aug 31, 2021
11:44AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2021   Benzinga
08:05AM EDT  Maxim Group Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7   Benzinga
Aug 24, 2021
08:17AM EDT  Palisade Bio Q2 EPS $(4.10) Down From $(0.67) YoY   Benzinga
08:15AM EDT  Palisade Bio, Inc.(Nasdaq: PALI) (Palisade or the Company), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the second quarter ending June 30, 2021.   GlobeNewswire Inc
Aug 20, 2021
09:27AM EDT  Palisade Bio Share Spike Higher; Co Announces $5.2M Investment By Yuma Regional Medical Center   Benzinga
09:25AM EDT  -- $5.2M invested at $3.45 stock price -- Funds to be used to advance clinical development of LB1148 -- Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used as standard of care for the protection and healing of the GI tract in surgical patients if approved by the FDA   GlobeNewswire Inc
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 29, 2021
08:24AM EDT  Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery   Benzinga
08:15AM EDT  Statistically significant 1.1-day acceleration in return of bowel function   GlobeNewswire Inc
Jul 13, 2021
10:18AM EDT  Palisade Bio, University of California Team Up For Target Identification, Discovery, Development   Benzinga
08:06AM EDT  Palisade Bio Says Enters Into Worldwide In-Licensing Agreement With University Of California For Technology To Support Target Identification, Drug Discovery And Clinical Development   Benzinga
08:01AM EDT  Palisade Bio Enters into Worldwide In-Licensing Agreement with   GlobeNewswire Inc
Jul 1, 2021
10:43AM EDT  Palisade Bio Receives Decision To Grant European Patent Titled, 'COMPOSITIONS FOR THE TREATMENT OF AUTODIGESTION'   Benzinga
Jun 15, 2021
08:15AM EDT  Palisade Bio Launches Clinical Steering Committee to Provide   GlobeNewswire Inc
Jun 7, 2021
03:52PM EDT  SEC Alleges Neuralstem Project Manager Holly Hand Learned Of Negative Drug Trial Results And Tipped Chad Callice; Watching Palisade Bio Shares   Benzinga
May 17, 2021
03:09PM EDT  Palisade Bio Granted Notice Of Allowance For U.S. Patent Titled 'COMPOSITIONS FOR THE TREATMENT OF AUTODIGESTION'   Benzinga
May 13, 2021
09:23AM EDT  Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions   Benzinga
07:10AM EDT  Palisade Bio Gets FDA Fast Track Designation For LB1148 For Reduction Of Adhesions Following Abdominal, Pelvic Surgery   RTTNews
07:02AM EDT  Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery   Benzinga
07:00AM EDT  LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery   GlobeNewswire Inc
May 7, 2021
09:09AM EDT  Palisade Bio, Newsoara Report Completion Of Phase 2 Study In Gastrointestinal Surgery Study In China   Benzinga
09:08AM EDT  Palisade Bio and Newsoara Announce Completion of Phase 2 Study in   GlobeNewswire Inc
May 4, 2021
08:00AM EDT  Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it will host a key opinion leader (KOL) webinar event on LB1148, the Companys lead asset for indications associated with GI Surgery, on Thursday, May 13, 2021 at 1:00pm Eastern Time.   GlobeNewswire Inc
Apr 27, 2021
04:02PM EDT  The combined company, Palisade Bio, Inc., is expected to commence trading on the Nasdaq Capital Market under the ticker symbol PALI on April 28, 2021   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC